About GreenLight Biosciences
GreenLight Biosciences is a biotechnology company that develops an RNA platform for agriculture and human health.
Headquarters
GreenLight Biosciences, Medford
Founded
2008-01-01
Industry
Agriculture, AgTech, Biotechnology, Life Science
Last Funding Type
Post Ipo Equity
Valuation
1
Total Funding
$449.50 million dollars
IPO Status
Delisted
Financial
Greenlight Biosciences may be growing as it has recently secured EPA registration for its new bioinsecticide, Calantha, which represents a significant milestone in the company's development and commercialization of sustainable agricultural products. This achievement indicates progress in product development and regulatory approval, which are critical for market access and revenue generation in the biotechnology and agriculture sectors. Furthermore, the attainment of EPA registration suggests that the company is successfully navigating the complex regulatory environment, which is essential for growth in the life sciences industry.
Greenlight Biosciences Inc. is focused on developing RNA-based solutions for agricultural and health applications. Their research includes lipid nanoparticle compositions for nucleic acid delivery, RNA-based methods to control fungal pathogens like Fusarium, and stable RNA formulations without sub-zero storage. They are also working on cell-free RNA production, RNA stabilization for agricultural use, and RNA constructs for therapeutic delivery. Additionally, they explore RNAi for pest control in bees and crops, nucleoside triphosphate and RNA production, and sugar production from starch. Each area of R&D aims to advance RNA technology in various fields.
GreenLight Biosciences has raised a total of $400,000 to compete with legacy agrichemical companies in the $280 billion market.
Greenlight Biosciences Inc. is focused on developing RNA-based solutions for agricultural and health applications. Their research includes lipid nanoparticle compositions for nucleic acid delivery, RNA-based methods to control fungal pathogens like Fusarium, and stable RNA formulations without sub-zero storage. They are also working on cell-free RNA production, RNA stabilization for agricultural use, and RNA constructs for therapeutic delivery. Additionally, they explore RNAi for pest control in bees and crops, nucleoside triphosphate and RNA production, and sugar production from starch. Each area of R&D aims to advance RNA technology in various fields.
GreenLight Biosciences has raised a total of $400,000 to compete with legacy agrichemical companies in the $280 billion market.
Funding Rounds
10
Number of Lead Investors
6
Total Funding Amount
$449.50 million dollars
Number of Investors
34